CD4 Effector T Cell Expansion to Identify Objective Responses to the CD40 Agonist Mitazalimab in Combination with Modified FOLFIRINOX (mffx) As First-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma (mpdac) in the OPTIMIZE-1 Study.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined